Isatuximab in Lung Transplant Recipients

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to determine the safety and feasibility of adding isatuximab to standard of care therapies in patients who will receive a lung transplant, but have significant antibodies against the donor (desensitization), or patients who have previously received a lung transplant and develop antibodies against the donor (antibody-mediated rejection, AMR). The study will compare the impact of isatuximab on the recurrence of antibodies after they have been removed from the blood by a process known as plasmapheresis that is standard of care for this condition. The use of isatuximab in lung transplant recipients is investigational, meaning it is not Food and Drug Administration (FDA) approved for use in lung transplant recipients. This study is a pilot study investigating the feasibility and safety of isatuximab in lung transplant patients. Isatuximab is an FDA approved drug indicated for the treatment of multiple myeloma. It may also be useful for transplant recipients with antibodies against the donor because it eliminates the cells that make antibodies.

Clinical Trial Description

This dual-arm pilot study will enroll approximately 6 patients undergoing lung transplantation at NYU Langone Health who are either receiving peri-transplant desensitization, or who are admitted for treatment of AMR. All patients will be treated with standard-of-care consisting of plasmaspheresis, IVIG, and rituximab. Additionally, the experimental agent, isatuximab, will be added to this treatment protocol. The patients will first receive 4 weekly doses of isatuximab, followed by 4 bi¬-weekly doses (total 8 doses given over 12 weeks). Patients will be followed with standard-of-care immunologic assessment consisting of weekly DSA assessment and flow cytometry crossmatch (only in the desensitization arm). Additionally, patients undergoing peri-transplant desensitization will have a bone marrow biopsy with pathologic examination and cell counts performed at the time of transplant and repeated at the 30-day bronchoscopy to assess for plasma cell elimination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05862766
Study type	Interventional
Source	NYU Langone Health
Contact	Tyler Lewis, PharmD
Phone	866-838-5864
Email	Tyler.lewis@nyulangone.org
Status	Not yet recruiting
Phase	Early Phase 1
Start date	July 1, 2024
Completion date	January 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02533596` - Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange	N/A
Completed	`NCT04367610` - Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Completed	`NCT05021484` - Felzartamab in Late Antibody-Mediated Rejection	Phase 2
Terminated	`NCT02120482` - Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study	N/A
Terminated	`NCT03744910` - Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients	Phase 3
Terminated	`NCT03221842` - Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients	Phase 3
Terminated	`NCT01895127` - Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation	Phase 2
Completed	`NCT02013037` - The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation	Phase 3
Recruiting	`NCT03737136` - Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR	N/A
Recruiting	`NCT05913596` - The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation	N/A
Active, not recruiting	`NCT04541914` - Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT	N/A
Withdrawn	`NCT03805178` - Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization	Phase 2
Recruiting	`NCT06112951` - A Prospective Randomized Trial of ECP in Subclinical AMR	N/A
Active, not recruiting	`NCT04897438` - Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection	N/A
Recruiting	`NCT05004493` - Biorepository and Registry for Plasma Exchange Patients
Completed	`NCT04026087` - Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation
Active, not recruiting	`NCT03994783` - Transplant Antibody-Mediated Rejection: Guiding Effective Treatments	Phase 3
Recruiting	`NCT04368962` - DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients
Completed	`NCT03444103` - A Pilot Trial of Clazakizumab in Late ABMR	Phase 2
Recruiting	`NCT05140018` - Incidence, Course and Outcome of ABMR in Kidney Transplantation

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.